A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer
David J. McConkey(The University of Texas MD Anderson Cancer Center), Woonyoung Choi(The University of Texas MD Anderson Cancer Center), Yu Shen(The University of Texas MD Anderson Cancer Center), I.-Ling Lee(The University of Texas MD Anderson Cancer Center), Sima P. Porten(The University of Texas MD Anderson Cancer Center), Surena F. Matin(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Paul G. Corn(The University of Texas MD Anderson Cancer Center), Randall E. Millikan(Essentia Health), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Bogdan Czerniak(The University of Texas MD Anderson Cancer Center), Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center)
Cited by 277Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis